# Orion Corporation, Orion Pharma

Organization · id `cardio:org-orion-corporation-orion-pharma` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Orion+Corporation%2C+Orion+Pharma>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Orion Corporation, Orion Pharma
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery (`cardio:ct-nct01294163`)
- Sponsors: Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial (`cardio:ct-nct02648464`)
- Sponsors: Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure (`cardio:ct-nct03437226`)

## Provenance

Content hash: 028e01e74a33b357d35c570238c63b293ec3d42cd6a60a55814dea0447f759a8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
